Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
We hypothesize that delayed graft function and ITBS events may be related to small blood
clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of
the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant
morbidity and mortality, and may ultimately result in a greater number of transplantable
livers and kidneys.
Phase:
N/A
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
Health Resources and Services Administration (HRSA)